- Home
- MURA vs RAPT Comparison
MURA vs RAPT Comparison
Compare MURA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- RAPT
- Stock Information
- Founded
- MURA 2013
- RAPT 2015
- Country
- MURA Ireland
- RAPT United States
- Employees
- MURA N/A
- RAPT N/A
- Industry
- MURA
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- RAPT Health Care
- Exchange
- MURA Nasdaq
- RAPT Nasdaq
- Market Cap
- MURA 57.2M
- RAPT 59.1M
- IPO Year
- MURA N/A
- RAPT 2019
- Fundamental
- Price
- MURA $4.00
- RAPT $1.20
- Analyst Decision
- MURA Strong Buy
- RAPT Hold
- Analyst Count
- MURA 4
- RAPT 10
- Target Price
- MURA $16.00
- RAPT $6.00
- AVG Volume (30 Days)
- MURA 239.2K
- RAPT 9.1M
- Earning Date
- MURA 11-13-2024
- RAPT 03-06-2025
- Dividend Yield
- MURA N/A
- RAPT N/A
- EPS Growth
- MURA N/A
- RAPT N/A
- EPS
- MURA N/A
- RAPT N/A
- Revenue
- MURA N/A
- RAPT N/A
- Revenue This Year
- MURA N/A
- RAPT N/A
- Revenue Next Year
- MURA N/A
- RAPT N/A
- P/E Ratio
- MURA N/A
- RAPT N/A
- Revenue Growth
- MURA N/A
- RAPT N/A
- 52 Week Low
- MURA $2.87
- RAPT $0.79
- 52 Week High
- MURA $5.62
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- MURA 66.06
- RAPT 43.92
- Support Level
- MURA $3.55
- RAPT $1.07
- Resistance Level
- MURA $4.05
- RAPT $1.29
- Average True Range (ATR)
- MURA 0.24
- RAPT 0.17
- MACD
- MURA 0.07
- RAPT -0.04
- Stochastic Oscillator
- MURA 91.35
- RAPT 15.43
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.